Electric Countershock

• 

  Subject Areas on Research

  • 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). 
  • 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). 
  • 2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). 
  • 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. 
  • 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing. 
  • 6-Month Outcomes in Patients With Implantable Cardioverter-Defibrillators Undergoing Renal Sympathetic Denervation for the Treatment of Refractory Ventricular Arrhythmias. 
  • A change of heart. 
  • A covariance-based algorithm: a novel technique for rhythm discrimination in ICDs. 
  • A four-shock Bayesian up-down estimator of the 80% effective defibrillation dose. 
  • A novel ultrasound technique to estimate right ventricular geometry during fibrillation. 
  • ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. 
  • ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). 
  • ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. 
  • ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Clinical Performance Measures for Atrial Fibrillation): developed in collaboration with the Heart Rhythm Society. 
  • Activation during ventricular defibrillation in open-chest dogs. Evidence of complete cessation and regeneration of ventricular fibrillation after unsuccessful shocks. 
  • Additional antitachycardia pacing programming strategies further reduce unnecessary implantable cardioverter-defibrillator shocks. 
  • Administrative Codes for Capturing In-Hospital Cardiac Arrest. 
  • Altering the topology of gap junctions a major therapeutic target for atrial fibrillation. 
  • Amplatzer vascular plug closure of a subclavian arteriovenous fistula associated with implantable cardioverter-defibrillator implantation. 
  • An International Multicenter Evaluation of Type 5 Long QT Syndrome: A Low Penetrant Primary Arrhythmic Condition. 
  • An unusual case of ventricular fibrillation. 
  • An up-down Bayesian, defibrillation efficacy estimator. 
  • Analysis of Temporal Trends and Variation in the Use of Defibrillation Testing in Contemporary Practice. 
  • Analysis of the defibrillation efficacy for 5-ms waveforms. 
  • Anesthetic management of an AAI pacemaker patient with paroxysmal atrial fibrillation during colorectal surgery. 
  • Antithrombotic therapy in atrial fibrillation. 
  • Applying the new STEMI guidelines: 2. Disturbances of cardiac rhythm after ST-segment elevation myocardial infarction. 
  • Association Between Comorbidities and Outcomes in Heart Failure Patients With and Without an Implantable Cardioverter-Defibrillator for Primary Prevention. 
  • Association Between Prompt Defibrillation and Epinephrine Treatment With Long-Term Survival After In-Hospital Cardiac Arrest. 
  • Association between myocardial substrate, implantable cardioverter defibrillator shocks and mortality in MADIT-CRT. 
  • Association of Bystander and First-Responder Intervention With Survival After Out-of-Hospital Cardiac Arrest in North Carolina, 2010-2013. 
  • Association of Public Health Initiatives With Outcomes for Out-of-Hospital Cardiac Arrest at Home and in Public Locations. 
  • Associations between understanding of current treatment intent, communication with healthcare providers, preferences for invasive life-sustaining interventions and decisional conflict: results from a survey of patients with advanced heart failure in Singapore. 
  • Atrial ejection force: a noninvasive assessment of atrial systolic function. 
  • Atrial fibrillation in heart failure: what should we do? 
  • Atrial fibrillation: conventional wisdom reappraised. 
  • Atrial fibrillation: rate control versus maintenance of sinus rhythm. 
  • Biomarkers in atrial fibrillation: investigating biologic plausibility, cause, and effect. 
  • Biphasic versus monophasic shock waveform for conversion of atrial fibrillation: the results of an international randomized, double-blind multicenter trial. 
  • COR-ART: A multicenter, randomized, double-blind, placebo-controlled dose-ranging study to evaluate single oral doses of vanoxerine for conversion of recent-onset atrial fibrillation or flutter to normal sinus rhythm. 
  • Cardiac mapping at Duke Medical Center. 
  • Cardiac potential and potential gradient fields generated by single, combined, and sequential shocks during ventricular defibrillation. 
  • Cardiac resuscitation in the operating room: reflections on how we can do better. 
  • Cardiac resynchronization therapy in heart failure patients: an update. 
  • Cardiac resynchronization therapy: Part 2--issues during and after device implantation and unresolved questions. 
  • Cardiac-resynchronization therapy for the prevention of heart-failure events. 
  • Cardioversion and subsequent quality of life and natural history of atrial fibrillation. 
  • Cardioversion from atrial fibrillation without prolonged anticoagulation with use of transesophageal echocardiography to exclude the presence of atrial thrombi. 
  • Cardioversion of nonrheumatic atrial fibrillation. Reduced thromboembolic complications with 4 weeks of precardioversion anticoagulation are related to atrial thrombus resolution. 
  • Catheter ablation for ventricular tachycardia in patients with an implantable cardioverter defibrillator (CALYPSO) pilot trial. 
  • Centers for Medicare and Medicaid Services' Decision to Reconsider Coverage Indications for ICDs: Where to Now? 
  • Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 1. 
  • Choosing the optimal monophasic and biphasic waveforms for ventricular defibrillation. 
  • Collaborative care for the wearable cardioverter defibrillator patient: Getting the patient and medical team "vested and active". 
  • Comparative Effectiveness of CRT-D Versus Defibrillator Alone in HF Patients With Moderate-to-Severe Chronic Kidney Disease. 
  • Comparative Effectiveness of Cardiac Resynchronization Therapy Among Patients With Heart Failure and Atrial Fibrillation: Findings From the National Cardiovascular Data Registry's Implantable Cardioverter-Defibrillator Registry. 
  • Comparative Effectiveness of Implantable Cardioverter Defibrillators for Primary Prevention in Women. 
  • Comparative Effectiveness of Primary Prevention Implantable Cardioverter-Defibrillators in Older Heart Failure Patients With Diabetes Mellitus. 
  • Comparison of activation during ventricular fibrillation and following unsuccessful defibrillation shocks in open-chest dogs. 
  • Comparison of defibrillation probability of success curves for an endocardial lead configuration with and without an inactive epicardial patch. 
  • Comparison of outcomes between pulseless electrical activity by electrocardiography and pulseless myocardial activity by echocardiography in out-of-hospital cardiac arrest; secondary analysis from a large, prospective study. 
  • Comparison of team-focused CPR vs standard CPR in resuscitation from out-of-hospital cardiac arrest: Results from a statewide quality improvement initiative. 
  • Comparison of upper limit of vulnerability and defibrillation probability of success curves using a nonthoracotomy lead system. 
  • Constructing a multichannel electrocardiography system from a few standardized, high-level components. 
  • Construction of a very high-density extracellular electrode array. 
  • Cost-effectiveness of automated external defibrillators on airlines. 
  • Current concepts for selecting the location, size and shape of defibrillation electrodes. 
  • Current density and electrically induced ventricular fibrillation. 
  • Death with an implantable cardioverter-defibrillator: a MADIT-II substudy. 
  • Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. 
  • Defibrillation and the geometry of the heart: a novel measurement with implications for defibrillation mechanisms. 
  • Defibrillation and the upper limit of vulnerability to fibrillation in a transthoracic guinea pig model. 
  • Defibrillation causes immediate cardiac dilation in humans. 
  • Defibrillation coil reversal: a rare cause of abnormal noise and inappropriate shocks. 
  • Defibrillation time intervals and outcomes of cardiac arrest in hospital: retrospective cohort study from Get With The Guidelines-Resuscitation registry. 
  • Defibrillation with low voltage using a left ventricular catheter and four cutaneous patch electrodes in dogs. 
  • Designation and distribution of events in the Multicenter UnSustained Tachycardia Trial (MUSTT). 
  • Determination of effects of internal countershock by direct cardiac recordings during normal rhythm. 
  • Disease understanding in patients newly diagnosed with atrial fibrillation. 
  • Do ICD lead recalls affect physician--or patient--behavior? If not, why not? 
  • Early administration of epinephrine (adrenaline) in patients with cardiac arrest with initial shockable rhythm in hospital: propensity score matched analysis. 
  • Early ambulation after 5 French diagnostic cardiac catheterization: results of a multicenter trial. 
  • Early cardioversion of atrial fibrillation facilitated by transesophageal echocardiography: short-term safety and impact on maintenance of sinus rhythm at 1 year. 
  • Early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. 
  • Effect of Novel Programming on Inappropriate Implantable Cardioverter-Defibrillator Therapy in Patients With Very Low Ejection Fraction (from A MADIT-RIT). 
  • Effect of cardiac resynchronization therapy and implantable cardioverter defibrillator on quality of life in patients with heart failure: a meta-analysis. 
  • Effect of defibrillation threshold testing on heart failure hospitalization or death in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). 
  • Effect of microscopic and macroscopic discontinuities on the response of cardiac tissue to defibrillating (stimulating) currents. 
  • Effect of pulse separation between two sequential biphasic shocks given over different lead configurations on ventricular defibrillation efficacy. 
  • Effect of rapid pacing and T-wave scanning on the relation between the defibrillation and upper-limit-of-vulnerability dose-response curves. 
  • Effective defibrillation in pigs using interleaved and common phase sequential biphasic shocks. 
  • Effectiveness of high rate and delayed detection ICD programming by race: A MADIT-RIT substudy. 
  • Effects of electroporation on the transmembrane potential distribution in a two-dimensional bidomain model of cardiac tissue. 
  • Effects of electroporation on transmembrane potential induced by defibrillation shocks. 
  • Effects of implantable cardioverter/defibrillator shock and antitachycardia pacing on anxiety and quality of life: A MADIT-RIT substudy. 
  • Effects of monophasic and biphasic shocks on action potentials during ventricular fibrillation in dogs. 
  • Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants After Cardioversion for Nonvalvular Atrial Fibrillation. 
  • Efficacy and safety of apixaban in patients after cardioversion for atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation). 
  • Electric field stimulation of excitable tissue. 
  • Electrophysiology in China: a special supplement. Introduction. 
  • Electroporation and shock-induced transmembrane potential in a cardiac fiber during defibrillation strength shocks. 
  • Epicardial mapping of ventricular defibrillation with monophasic and biphasic shocks in dogs. 
  • Epicardial sock mapping following monophasic and biphasic shocks of equal voltage with an endocardial lead system. 
  • Estimating defibrillation efficacy using combined upper limit of vulnerability and defibrillation testing. 
  • Estimating the 95% effective defibrillation dose 
  • European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Africa (CASSA), and Latin American Heart Rhythm Society (LAHRS). 
  • Evaluation of outpatients experiencing implantable cardioverter defibrillator shocks associated with minimal symptoms. 
  • Evaluation of the effect of transthoracic cardioversion from ventricular tachycardia to sinus rhythm on left atrial mechanical function. 
  • Evolution of the CCU from rhythm, function and protection to reperfusion and beyond: a personal journey and perspective. 
  • Experimental cardiac tachyarrhythmias in guinea pigs. 
  • Experimental evidence of improved transthoracic defibrillation with electroporation-enhancing pulses. 
  • Experimental verification of theoretical predictions concerning the optimum defibrillation waveform. 
  • Factors Associated With Large Improvements in Health-Related Quality of Life in Patients With Atrial Fibrillation: Results From ORBIT-AF. 
  • Feasibility of a Randomized Clinical Trial of Cardiac Resynchronization Therapy With or Without an Implantable Defibrillator in Older Patients. 
  • Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks. 
  • Field stimulation of cardiac fibers with random spatial structure. 
  • Finite element analysis of bioelectric phenomena. 
  • Follow-up of patients with new cardiovascular implantable electronic devices: are experts' recommendations implemented in routine clinical practice? 
  • Future Research Prioritization: Implantable Cardioverter-Defibrillator Therapy in Older Patients. 
  • HAZARDS OF ELECTRIC SHOCK IN CARDIOLOGY. 
  • Heart Watch Study: protocol for a pragmatic randomised controlled trial. 
  • High and low strength nonsynchronized shocks given during canine ventricular tachycardia. 
  • Impact of Tachyarrhythmia Detection Rate and Time from Detection to Shock on Outcomes in Nationwide US Practice. 
  • Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. 
  • Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions. 
  • Implantable cardioverter-defibrillator lead revision following left ventricular assist device implantation. 
  • Implantable intravascular defibrillator: evaluation of defibrillation waveforms with inferior vena cava electrode system. 
  • Implementation of a National 5-Year Plan for Prehospital Emergency Care in Singapore and Impact on Out-of-Hospital Cardiac Arrest Outcomes From 2011 to 2016. 
  • Importance of electrode conductive surface area and edge effects on ventricular defibrillation efficacy. 
  • Improved defibrillation thresholds with large contoured epicardial electrodes and biphasic waveforms. 
  • In-hospital management of patients with atrial flutter. 
  • Inappropriate implantable cardioverter-defibrillator shocks in MADIT II: frequency, mechanisms, predictors, and survival impact. 
  • Inclusion of junction elements in a linear cardiac model through secondary sources: application to defibrillation. 
  • Incomplete relaxation between beats after myocardial hypoxia and ischemia. 
  • Increasing the computational efficiency of a bidomain model of defibrillation using a time-dependent activating function. 
  • Influence of epicardial patches on defibrillation threshold with nonthoracotomy lead configurations. 
  • Influence of gender on arrhythmia characteristics and outcome in the Multicenter UnSustained Tachycardia Trial. 
  • Influence of shock strength and timing on induction of ventricular arrhythmias in dogs. 
  • Initial Interventions for Out-of-Hospital Cardiac Arrest--Reply. 
  • Internal cardioversion in two patients with atrial fibrillation refractory to external cardioversion. 
  • Interventional strategies associated with improvements in survival for out-of-hospital cardiac arrests in Singapore over 10 years. 
  • Is the second phase of a biphasic defibrillation waveform the defibrillating phase? 
  • Large sample test of defibrillation waveform sensitivity. 
  • Left ventricular geometry immediately following defibrillation: shock-induced relaxation. 
  • Long-Term Outcomes of Implantable Cardioverter-Defibrillator Therapy in the SCD-HeFT. 
  • Long-term clinical course of patients after termination of ventricular tachyarrhythmia by an implanted defibrillator. 
  • MY APPROACH to the risk stratification of patients for sudden cardiac death. 
  • Management and outcome of patients with atrial fibrillation during acute myocardial infarction: the GUSTO-III experience. Global use of strategies to open occluded coronary arteries. 
  • Management of postoperative atrial fibrillation and subsequent outcomes in contemporary patients undergoing cardiac surgery: insights from the Society of Thoracic Surgeons CAPS-Care Atrial Fibrillation Registry. 
  • Mechanism of cardiac defibrillation. A different point of view. 
  • Minimum energy single-shock internal atrial defibrillation in sheep. 
  • Mode of death in advanced heart failure: the Comparison of Medical, Pacing, and Defibrillation Therapies in Heart Failure (COMPANION) trial. 
  • Monophasic and biphasic shock for transthoracic conversion of atrial fibrillation: Systematic review and network meta-analysis. 
  • More bad news for cardiac resynchronization therapy in atrial fibrillation patients: what to do? 
  • Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT). 
  • Multistate 5-Year Initiative to Improve Care for Out-of-Hospital Cardiac Arrest: Primary Results From the HeartRescue Project. 
  • Mystery of biphasic defibrillation waveform efficacy is it calcium? 
  • Non-vitamin K antagonist oral anticoagulants in cardioversion of atrial fibrillation: a network meta-analysis. 
  • Novel ICD Programming and Inappropriate ICD Therapy in CRT-D Versus ICD Patients: A MADIT-RIT Sub-Study. 
  • One-dimensional model of cardiac defibrillation. 
  • Open-thorax guinea pig model for defibrillation. 
  • Optical measurements of transmembrane potential changes during electric field stimulation of ventricular cells. 
  • Optimal management of Riata leads with no known electrical abnormalities or externalization: a decision analysis. 
  • Optimal timing of implantable cardioverter-defibrillator implantation after myocardial infarction: a decision analysis. 
  • Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. 
  • Oral anticoagulation management in patients with atrial fibrillation undergoing cardiac implantable electronic device implantation. 
  • Outcome in African Americans and other minorities in the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). 
  • Outcomes after cardioversion and atrial fibrillation ablation in patients treated with rivaroxaban and warfarin in the ROCKET AF trial. 
  • Outcomes after nonemergent electrical cardioversion for atrial arrhythmias. 
  • Outcomes associated with warfarin use in older patients with heart failure and atrial fibrillation and a cardiovascular implantable electronic device: findings from the ADHERE registry linked to Medicare claims. 
  • Outcomes following cardioversion for patients with cardiac amyloidosis and atrial fibrillation or atrial flutter. 
  • Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial. 
  • PR interval identifies clinical response in patients with non-left bundle branch block: a Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy substudy. 
  • Patterns of Care for Atrial Fibrillation Before, During, and at Discharge From Hospitalization: From the Get With The Guidelines-Atrial Fibrillation Registry. 
  • Patterns of oral anticoagulation use with cardioversion in clinical practice. 
  • Periodic conductivity as a mechanism for cardiac stimulation and defibrillation. 
  • Perioperative morbidity and mortality in combined vs. staged approaches to carotid and coronary revascularization. 
  • Perplexing Results From the PRAETORIAN Trial: Revisiting the Debate About the Value of Antitachycardia Pacing. 
  • Physicians' knowledge and attitudes regarding implantable cardioverter-defibrillators. 
  • Physicians' perceptions of shared decision-making for implantable cardioverter-defibrillators: Results of a physician survey. 
  • Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. 
  • Pre-hospital synthesized 12-lead ECG ischemia monitoring with trans-telephonic transmission in acute coronary syndromes: pilot study results of the ST SMART trial. 
  • Predicting the potential gradient field in ventricular fibrillation from shocks delivered in paced rhythm. 
  • Predictors of an inadequate defibrillation safety margin at ICD implantation: insights from the National Cardiovascular Data Registry. 
  • Pregnancy course and outcomes in women with arrhythmogenic right ventricular cardiomyopathy. 
  • Prescription of Guideline-Recommended Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy Among Patients Hospitalized With Heart Failure and Varying Degrees of Renal Function. 
  • Primary prevention implantable cardioverter-defibrillators in older racial and ethnic minority patients. 
  • Progress toward the prevention and treatment of atrial fibrillation: A summary of the Heart Rhythm Society Research Forum on the Treatment and Prevention of Atrial Fibrillation, Washington, DC, December 9-10, 2013. 
  • Prolongation of repolarization time by electric field stimulation with monophasic and biphasic shocks in open-chest dogs. 
  • Prolonged cardiopulmonary resuscitation and outcomes after out-of-hospital cardiac arrest. 
  • Pulmonary edema post-cardioversion: a potential calcium signalling problem. 
  • Racial differences in survival after in-hospital cardiac arrest. 
  • Random nature of fibrillation leads to the probabilistic nature of defibrillation. 
  • Rate Control versus Rhythm Control for Atrial Fibrillation after Cardiac Surgery. 
  • Rate versus rhythm control and outcomes in patients with atrial fibrillation and chronic kidney disease: data from the GUSTO-III Trial. 
  • Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. 
  • Rationale and design for the Defibrillators to Reduce Risk by Magnetic Resonance Imaging Evaluation (DETERMINE) trial. 
  • Rationale and design of the First Brazilian Cardiovascular Registry of Atrial Fibrillation: The RECALL study. 
  • Rationale and design of the Home Automatic External Defibrillator Trial (HAT). 
  • Reduction in Inappropriate ICD Therapy in MADIT-RIT Patients Without History of Atrial Tachyarrhythmia. 
  • Remote monitoring of cardiac implantable electronic devices (CIED). 
  • Response of relatively refractory canine myocardium to monophasic and biphasic shocks. 
  • Response to letter regarding, "PR interval identifies clinical response in patients with non-left bundle branch block: a multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy sub-study" by Kutyifa et al. 
  • Review of advanced heart failure device diagnostics examined in clinical trials and the potential benefit from monitoring capabilities. 
  • Rhythm control in atrial fibrillation. 
  • Rhythm control versus rate control for atrial fibrillation and heart failure. 
  • Rhythm versus rate control in the contemporary management of atrial fibrillation in-hospital. 
  • Selecting an antiarrhythmic agent for atrial fibrillation should be a patient-specific, data-driven decision. 
  • Sex Differences in Inappropriate ICD Device Therapies: MADIT-II and MADIT-CRT. 
  • Significance of atrial fibrillation during acute myocardial infarction, and its current management: insights from the GUSTO-3 trial. 
  • Spatial potential and current distributions along transvenous defibrillation electrodes: variation of electrode characteristics. 
  • Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. 
  • Strategies for improving survival after in-hospital cardiac arrest in the United States: 2013 consensus recommendations: a consensus statement from the American Heart Association. 
  • Strength-duration and probability of success curves for defibrillation with biphasic waveforms. 
  • Sudden cardiac arrest in ESRD patients. 
  • Surface coverage effects on defibrillation impedance for transvenous electrodes. 
  • Survival after primary prevention implantable cardioverter-defibrillator placement among patients with chronic kidney disease. 
  • Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. 
  • Survival in Women Versus Men Following Implantation of Pacemakers, Defibrillators, and Cardiac Resynchronization Therapy Devices in a Large, Nationwide Cohort. 
  • THE NATURE AND MANAGEMENT OF ELECTRIC SHOCK. 
  • Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. 
  • The Association of Duration of participation in get with the guidelines-resuscitation with quality of Care for in-Hospital Cardiac Arrest. 
  • The Relationship Between Level of Adherence to Automatic Wireless Remote Monitoring and Survival in Pacemaker and Defibrillator Patients. 
  • The clinical implications of cumulative right ventricular pacing in the multicenter automatic defibrillator trial II. 
  • The defibrillation efficacy of high frequency alternating current sinusoidal waveforms in guinea pigs. 
  • The effect of cardiac compression on defibrillation efficacy and the upper limit of vulnerability. 
  • The effect of inducing ventricular fibrillation with 50-Hz pacing versus T wave stimulation on the ability to defibrillate. 
  • The effect of intermittent atrial tachyarrhythmia on heart failure or death in cardiac resynchronization therapy with defibrillator versus implantable cardioverter-defibrillator patients: a MADIT-CRT substudy (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). 
  • The efficacy and safety of cardiac resynchronization therapy combined with implantable cardioverter defibrillator for heart failure: a meta-analysis of 5674 patients. 
  • The nitric oxide synthase inhibitor N(G)-nitro-L-arginine decreases defibrillation-induced free radical generation. 
  • The nitric oxide synthase inhibitor N(G)-nitro-L-arginine decreases defibrillation-induced free radical generation. 
  • The potential gradient field created by epicardial defibrillation electrodes in dogs. 
  • The probability of defibrillation success and the incidence of postshock arrhythmia as a function of shock strength. 
  • The role of bystanders, first responders, and emergency medical service providers in timely defibrillation and related outcomes after out-of-hospital cardiac arrest: Results from a statewide registry. 
  • The ventricular defibrillation and upper limit of vulnerability dose-response curves. 
  • Therapies to prevent heart failure post-myocardial infarction. 
  • Three-dimensional potential gradient fields generated by intracardiac catheter and cutaneous patch electrodes. 
  • Thromboembolism after negative TEE. 
  • Transesophageal echocardiographically facilitated early cardioversion from atrial fibrillation using short-term anticoagulation: final results of a prospective 4.5-year study. 
  • Transesophageal echocardiography before cardioversion. 
  • Transesophageal echocardiography versus oral anticoagulation before electrical cardioversion of atrial fibrillation: what about atrial clot size? 
  • Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary. 
  • Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. 
  • Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. 
  • Virtual electrode effects in transvenous defibrillation-modulation by structure and interface: evidence from bidomain simulations and optical mapping. 
  • Wearable Cardioverter Defibrillator "The Lifevest": Device Design, Limitations, and Areas of Improvement. 
  • Why are (only) some infarcted hearts arrhythmogenic? 
  • Why do some patients have high defibrillation thresholds at defibrillator implantation? Answers from basic research. 
• 

  Keywords of People

  • Alexander, John Hunter Peel, Professor of Medicine, Medicine, Cardiology
  • Dupre, Matthew E., Associate Professor in Population Health Sciences, Center for the Study of Aging and Human Development
  • Henriquez, Craig S., Professor of Biomedical Engineering, Biomedical Engineering
  • Middleton, John Paul, Professor of Medicine, Medicine, Nephrology